Get the Stockscreener App
0.4285
0.23%
-0.001
Theriva Biologics Inc stock is traded at $0.4285, with a volume of 194.88K.
It is down -0.23% in the last 24 hours and down -13.24% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.4295
Open:
$0.4208
24h Volume:
194.88K
Relative Volume:
0.25
Market Cap:
$4.11M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.3694
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
-7.45%
1M Performance:
-13.24%
6M Performance:
-72.35%
1Y Performance:
-99.47%
1-Day Range:
$0.4207
$0.436
1-Week Range:
$0.4014
$0.47
52-Week Range:
$0.3654
$144.38
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.4285 | 4.22M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Theriva Biologics Inc Stock (TOVX) Latest News
Technical Models Detect Momentum Build in Theriva Biologics Inc.2025 Big Picture & Precise Buy Zone Tips - thegnnews.com
Can Theriva Biologics Inc. rally from current levelsQuarterly Portfolio Report & Consistent Growth Stock Picks - Newser
What MACD signals say about Theriva Biologics Inc.Portfolio Update Summary & Long-Term Safe Investment Plans - Newser
Theriva Biologics Inc. stock trend forecastJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - Newser
What recovery options are there for Theriva Biologics Inc.Weekly Risk Summary & Safe Capital Growth Stock Tips - Newser
Can technical indicators confirm Theriva Biologics Inc.’s reversalWeekly Gains Report & Weekly Market Pulse Alerts - Newser
Heatmap analysis for Theriva Biologics Inc. and competitorsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser
Does Theriva Biologics Inc. qualify in momentum factor screeningBreakout Watch & Comprehensive Market Scan Reports - Newser
Full technical analysis of Theriva Biologics Inc. stockMarket Activity Summary & Consistent Income Trade Recommendations - Newser
Can trapped investors hope for a rebound in Theriva Biologics Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Building trade automation scripts for Theriva Biologics Inc.Trend Reversal & Low Volatility Stock Recommendations - Newser
Tools to monitor Theriva Biologics Inc. recovery probabilityJuly 2025 Trends & Weekly Market Pulse Alerts - Newser
How high can Theriva Biologics Inc. stock price go in 2025Earnings Beat & Free Community Consensus Stock Picks - Newser
Can Theriva Biologics Inc. expand its profit marginsBond Market & Real-Time Volume Surge Alerts - thegnnews.com
Will Theriva Biologics Inc. stock go up soonJuly 2025 Volume & Daily Entry Point Alerts - Newser
Is Theriva Biologics Inc. a candidate for recovery play2025 Growth vs Value & Daily Volume Surge Trade Alerts - Newser
How hedge fund analytics apply to Theriva Biologics Inc. stockMarket Performance Summary & Precise Swing Trade Alerts - Newser
What makes Theriva Biologics Inc. stock price move sharplyMarket Risk Summary & Expert Verified Movement Alerts - Newser
Is Theriva Biologics Inc. stock reversal real or fakeTrade Ideas & AI Enhanced Trading Signals - Newser
Is Theriva Biologics Inc. forming a reversal patternEarnings Overview Summary & Momentum Based Trading Signals - Newser
Will Theriva Biologics Inc. face regulatory challengesEarnings Growth Report & Daily Volume Surge Trade Alerts - mustnews.co.kr
Theriva Biologics Faces Financial Risks Amid Shifting Trade Policies and Tariffs - MSN
Theriva Biologics Reports Promising Trial Results and Financials - TipRanks
Sectors Driving Future Growth for Theriva Biologics Inc. StockMarket Trend Review & Reliable Entry Point Alerts - Newser
Why Theriva Biologics Inc. stock attracts strong analyst attentionTrade Risk Assessment & Daily Volume Surge Trade Alerts - Newser
Trendline Breach Raises Concern for Theriva Biologics Inc. InvestorsQuarterly Portfolio Review & Risk Controlled Swing Trade Alerts - 선데이타임즈
Os Therapies Incorporated shares rise 1.74% intraday after Theriva Biologics reported positive Phase 2b VIRAGE trial results. - AInvest
Analyzing net buyer seller activity in Theriva Biologics Inc.Trade Risk Summary & Safe Entry Zone Identification - Newser
Theriva Biologics Inc. stock daily chart insightsEarnings Miss & Short-Term High Return Strategies - Newser
Theriva Biologics Inc. Crosses 200 Day MA — Signal or NoiseEntry Zone Strategy for Consistent Profit Shared - beatles.ru
Theriva Biologics Reports Key Operational Milestones and Financial Results for Q1 2025 - AInvest
Theriva Biologics: Q2 Earnings Snapshot - Connecticut Post
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Cap:
|
Volume (24h):